0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > Fc gamma RIII / CD16 > FC6-C52H9

Cynomolgus Fc gamma RIII / CD16 Protein, His Tag (MALS & BLI verified)

Order Now

  • Synonym
    FCGR3
  • Source
    Cynomolgus CD16, His Tag(FC6-C52H9) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # Q8SPW2-1).
    Predicted N-terminus: Gly 17
  • Molecular Characterization
    Fc gamma RIII / CD16 Structure

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 23.8 kDa. The protein migrates as 35-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Fc gamma RIII / CD16 SDS-PAGE

Cynomolgus CD16, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS
Fc gamma RIII / CD16 MALS images

The purity of Cynomolgus CD16, His Tag (Cat. No. FC6-C52H9) is more than 90% and the molecular weight of this protein is around 30-40 kDa verified by SEC-MALS.

Bioactivity-ELISA
 Fc gamma RIII / CD16 ELISA

Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Cynomolgus CD16, His Tag (Cat. No. FC6-C52H9) with a linear range of 39-313 ng/mL (QC tested).

Bioactivity-SPR
 Fc gamma RIII / CD16 SPR

Captured Cynomolgus CD16, His Tag (Cat. No. FC6-C52H9) on CM5 chip via anti-His antibody can bind MabThera® (Rituximab) with an affinity constant of 0.206 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

Bioactivity-BLI
 Fc gamma RIII / CD16 BLI

Loaded Cynomolgus CD16, His Tag (Cat. No. FC6-C52H9) on HIS1K Biosensor, can bind Rituximab with an affinity constant of 0.287 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

 Fc gamma RIII / CD16 BLI

Loaded Herceptin on Protein A Biosensor, can bind Cynomolgus CD16, His Tag (Cat. No. FC6-C52H9) with an affinity constant of 0.31 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

 Fc gamma RIII / CD16 BLI

Loaded Herceptin on FAB2G Biosensor, can bind Cynomolgus CD16, His Tag (Cat. No. FC6-C52H9) with an affinity constant of 0.23 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.
    CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €220.00

Price(EUR) : €280.00

Price(EUR) : €2000.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:12 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message